Title: Evaluation of two RT-PCR techniques for SARS-CoV-2 RNA detection in 1

- 2 serum for microbiological diagnosis
- 4 Author Names and Affiliations:
- 5 Alexandra Martín Ramírez BSc.¹, Nelly Daniela Zurita Cruz PharmD.¹, Ainhoa
- 6 Gutiérrez-Cobos MD., PhD.^{1*}, Diego Aníbal Rodríguez Serrano MD., PhD.², Isidoro
- González Álvaro MD., PhD.³, Emilia Roy Vallejo MD.⁴, Sara Gómez de Frutos 7
- PharmD. ¹, Leticia Fontán García-Rodrigo PharmD. ¹, Laura Cardeñoso Domingo 8
- 9 PharmD., PhD. 1.
- 11 Affiliations:
- ¹Clinical Microbiology Departament. Hospital Universitario de la Princesa, Madrid, 12
- 13 Spain.

10

17

19

- 14 ²Intesive Care Department, Hospital Universitario de la Princesa, Madrid, Spain.
- 15 ³Reumatology Department, Hospital Universitario de la Princesa, Madrid, Spain.
- 16 ⁴Internal Medicine Department, Hospital Universitario de la Princesa, Madrid, Spain.
- 18 A.M.R and N.D.Z.C contributed equally to this article.
- 20 Corresponding author:
- 21 Ainhoa Gutiérrez Cobos, MD, PhD.
- 22 Clinical Microbiology Departament . Hospital Universitario de la Princesa
- C/Diego de León 62 23
- $\frac{28006\ Madrid.\ Spain}{\text{NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.}$

- 25 ainhoa.gutierrez@salud.madrid.org
- ainhoagutierrezcobos@gmail.com 26
- 27 Phone: +34 91 520 2103

ABSTRACT

28

52

29 Presence of SARS-CoV-2 RNA in serum (viraemia) in COVID-19 patients has been 30 related to poor prognosis and death. 31 The aim of this study was to evaluate the ability of two commercial reverse real-time-32 PCR (rRT-PCR) kits, cobas® SARS-CoV-2 (Cobas® test) and TaqPath™ COVID-19 CE-IVD RT-PCR Kit (TaqpathTM test), to detect viraemia in COVID-19 patients and 33 34 their implementation as routine diagnosis in microbiology laboratory. 35 This retrospective cohort study was conducted with 203 adult patients admitted to 36 Hospital Universitario de La Princesa, (89 Intensive Care Unit and 114 ward) with at 37 least one serum sample collected in the first 48 hours from admission. A total 265 38 serum samples were included for study. 39 Evaluation of both rRT-PCR techniques was performed comparing with the gold 40 standard, a Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit; considering 41 at least one target as a positive result. 42 Comparison of Cobas® test and TaqpathTM test with the gold standard method, showed 43 high values of specificity (93.75 and 92.19 respectively) and Positive Predictive Value (92.92 and 99.88 respectively). Nevertheless, sensitivity (53.72 and 73.63 respectively) 44 45 and Negative Predictive Value (32.53 and 42.99 respectively) were lower; Kappa values were 0.35 for cobas® test and 0.56 for TagpathTM test. 46 47 For both techniques, differences of viraemia detection between the ICU and non-ICU patients were significant (p≤0.001). 48 49 Consequently, SARS-CoV-2 viraemia positive results obtained by both rRT-PCR 50 should be considered good tools and may help in handling COVID-19 patients. 51 Moreover, these methods could be easily integrated in the routine laboratory COVID-19

diagnosis and may open new strategies based on an early COVID-19 treatment.

KEY WORDS: SARS-CoV-2, RNA, serum.

Introduction

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Coronavirus disease 2019 (COVID-19) is caused by a new type of coronavirus (SARS-CoV-2), that causes a severe acute respiratory syndrome. This novel coronavirus was first described in December 2019 in the city of Wuhan, China (1). At the first of November of 2020, more than a million deaths has been reported worldwide (2). Patients with COVID-19 may develop mild, moderate or severe symptoms like severe pneumonia, acute respiratory distress syndrome (ARDS) or multiple organ failure (3). To reduce the number of people who may end up with these severe symptoms, it is important to improve the diagnosis and, above all, to find tools that help us predict which patients will have a worse clinical outcome. Since the beginning of the COVID-19 pandemic, the samples that have been used the most for the diagnosis have been those of the respiratory tract. Lately it has been reported that the patient's serum may be another sample to consider due to the fact that the presence of RNA of SARS-CoV-2 in serum (called viraemia in this study) is related to unfavorable clinical outcomes and multi-organ damage (4, 5). This has been observed also in 2004, with 75% of the patients studied presenting RNA of SARS-CoV in blood samples (6). The most common tool to detect RNA of SARS-CoV-2 is the real time reverse transcription polymerase chain reaction (rRT-PCR). This technique is highly sensitive, especially if it detects more than two target regions (7). Although most rRT-PCR tests are performed on respiratory tract samples, the genetic material of this novel coronavirus can be detected in other samples also in serum, peripheral blood, feces and other anatomical parts (8). While the faculty of rRT-PCR for respiratory tract samples is well studied, for other kind of samples, as serum, it is not. Therefore, it is important to carry out comparative studies of the different RT-PCRs available to determine the capacity of these techniques to detect SARS-CoV-2 viraemia.

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

The aim of this study is the evaluation the ability of two commercial rRT-PCR assays (cobas® SARS-CoV-2 Test, Roche Diagnostics, USA and TagPathTM COVID-19 CE-IVD RT-PCR Kit, Thermo Fisher Scientific, USA), used in daily routine practice of COVID-19 diagnosis, to detect SARS-CoV-2 viraemia; and their implementation in a microbiology laboratory. **Material and Methods** Patients and samples This retrospective cohort study was conducted with 203 adult patients admitted to Hospital Universitario de La Princesa, a tertiary level hospital in Madrid (Spain), between March 1st and April 30th, with at least one serum sample collected in the first 48 hours from admission. All patients were symptomatic, with infection by SARS-CoV-2 confirmed by a positive PCR on a nasopharyngeal swab sample. Eighty nine were admitted to the ICU (Intensive Care Unit) with a median age of 65 years (IQR 69-72) and 71.3% male sex; and 114 were admitted to the general ward with a median age of 64 years; (IQR 54.3-72) and 66.4% of them men. Serum sampling was part of routine clinical practice. Some patients (50) had subsequent serum samples, which were collected during their hospital admission as part of their routine management. A total of 265 serum samples were included for this study. All samples were conserved at -20 °C until they were tested. Design of Study Serum samples were tested with two rRT-PCR: cobas® SARS-COV-2 test (cobas® test), a qualitative assay for detection of SARS-CoV-2 RNA; and TaqPathTM COVID-

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

19 CE-IVD RT-PCR Kit (TaqPath™ test), a multiplex RT-PCR assay for qualitative detection of nucleic acids of SARS-CoV-2. Both are used for routine detection of SARS-CoV-2 from nasopharyngeal swab samples at our hospital. Results obtained by both techniques were compared with results obtained by Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (Sansure Biotech Inc., China), a multiplex PCR test for qualitative detection of nucleic acids of SARS-CoV-2. This technique was the gold standard method due to it has CE (European Conformity In Vitro Device) and FDA (Food and Drug Administration) authorization for use in blood samples. Sansure Biotech reported a positive agreement of the test of 94.34% (95% CI: 84.34% ~ 98.82%), and a negative agreement of 98.96 % (95% CI: 96.31% ~ 99.87 %), in a clinical evaluation performed for the Submission to FDA EUA (Emergency Use Authorization) (9). Sample processing Test assay of all the three rRT-PCR was carried out with 400 µL of serum, treated previously for virus inactivation with lysis buffer. Cobas® test The assay detects a fragment of the orf-1ab region, specific of SARS-COV-2; and a conserved region of e gene, a structural enveloped gene, for pan-sarbecovirus detection. Test was performed by cobas® 6800 System (Roche Diagnostics, USA); an automatic platform of nucleic acids extraction and RT-PCR amplification and detection. Serum samples were processed according to manufacturer's indications, following the same

protocol used for SARS-CoV-2 detection in respiratory samples. Results were analyzed

and interpreted automatically by the cobas® 6800/8800 Software version 1.02.12.1002.

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

from their first serum sample.

TaqPathTM test and Gold Standard Method test TagPathTM test and gold standard method require a previous nucleic acid extraction from sample, which was performed by the automatic eMAG® Nucleic Acid Extraction System (Biomerieux, France). Extraction was carried out according to eMAG® manufacturer's directions, obtaining purified RNA in 60 µL of elution buffer, which was used to performed both assays. TaqPathTM test detects three specific SARS-CoV-2 genomic regions: orf-1ab, s, and n genes and was carried out using 5 µL of purified RNA, according to the manufacturer's instructions. Gold standard test detects two specific regions of SARS-CoV-2 genome: orf-1ab and n genes. The nucleic acid amplification was performed according to the kit manufacturer's indications using 10 µL of purified RNA. Both rRT-PCR tests were performed by QuantStudio™ 5 Real Time PCR System (Applied Biosystems, USA). Amplification curves were analyzed with QuantStudioTM Design and Analysis software version 2.4.3 (Applied Biosystems, USA). Interpretation of results were done by a clinical microbiologist, means of the amplification curves analysis, considering for a positive target detection: a) a Cycle threshold (Ct) cutoff value of 40; b) curves with typical S-shape or without plateau. Analysis of results Detection of at least one target was considered as a positive result. Evaluation of viraemia in patients was carried on considering only the results obtained

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

found (p=0.14).

Results obtained from all the 265 samples collected were analyzed for the techniques assessment. Statistical analysis was performed using SPSS 25.0 (IBM Corp., USA). Continuous and categorical variables were presented as median (interquartile range, IQR) and n (%), respectively. To analyze differences between detection of viraemia by each technique in patients, according if they have been admitted at ICU or not, a χ^2 test was performed. The Ct of any detected target was recorded and it was calculated the median, interquartile range (IQR) and the 95th percentile for each one. Sensitivity, specificity, positive and negative predictive values and Cohen's Kappa coefficient were calculated for cobas® test and TaqPathTM test, in comparison with the gold standard method. **Results** Viraemia detection in patients The cobas® test detected viraemia in 50,2% of patients recruited, showing a 65,2% and 38,6 % of positive viraemia detection for ICU and non-ICU admitted patients, respectively. On the other hand, TaqPathTM test detected viraemia in 62,6% of of all patients recruited, with a viraemia detection in 75,3 % of patients admitted in ICU, and

52,6% in those patients not admitted at ICU had a positive result. For both techniques,

differences of viraemia detection between the ICU and non-ICU patients were

Furthermore, the gold standard assay was able to detect the presence of RNA SARS-

Cov-2 in 80,8% of patients, with the following distribution: 85.4% and 77.2% for ICU

or Non-ICU patients, respectively. No significant differences between both groups were

significant ($p \le 0.001$). Results are shown in Table 1.

172 Table 1: Viraemia detection in patients admitted at ICU or in ward by both evaluated 173 techniques.

		Ward (%)	ICU (%)	Total	p
Cobas® SARS- CoV-2	Negative	70 (61.4)	31 (34.8)	101 (49.8)	
	Positive	44 (38.6)	58 (65.2)	102 (50.2)	0.0002
	Total	114	89	203	
	Negative	54 (47.4)	22 (24.7)	76 (37.4%)	
TaqPath™ COVID-19	Positive	60 (52.6)	67 (75.3)	127 (62.6)	0.001
COVID-17	Total	114	89	203	

p value calculated by χ^2 test

174

175

176

177

178

179

180

181

182

183

Assessment of serum samples

A total of 265 serum samples were analyzed by both rRT-PCR methods: cobas® test and-TaqPathTM test.

Comparison between cobas® test and the gold standard showed a 65.66% of concordance, with a kappa coefficient of 0.35. On other hand, comparison of TaqPathTM test showed a concordance of 78.11%. A kappa value of 0.52 was obtained. Summarized results of sensitivity, specificity, positive and negative predictive values of both techniques are shown in Table 2.

Table 2: Sensitivity, Specificity, positive and negative predictive values and their confidence intervals (95%) of cobas® test and TaqPathTM test compared to the gold standard method.

Assay		Value (%)	CI (9	95%)
Cobas® test	Sensitivity	56.72	49.62	63.81
	Specificity	93.75	87.04	100
Codas@ test	Positive predictive value	96.61	92.92	100
	Negative predictive value	40.82	32.53	49.1
TaqPath™ Test	Sensitivity	73.63	67.29	79.97
	Specificity	92.19	84.83	99.54
	Positive predictive value	96.73	93.59	99.88
	Negative predictive value	52.68	42.99	62.37

*CI: confidence interval

184

185

186

187

188

189

190

191

192

193

194

195

Median Ct value of cobas® test targets detected were 36.2 (IQR 34.2-37.1) for e gene, and 32.7 (IQR 32.1-34.1) for orflab gene. The 95th percentiles were 38.72 and 35.21 for e and orflab genes, respectively. On the other hand, median Ct values for each target detected by TaqPathTM test were: 31.91 (IQR 29.92-33.27); 32.46 (30.65-34.31) and 31.81 (30.01-32.92) for s, n and orflab genes respectively, and the 95^{th} percentile of Ct was 36.91, 37.17 and 37.04 for s, n and orflab genes respectively. Ct values of TaqPathTM test are shown in Table 3.

Table 3: Number of samples detected with TaqPath[™] test in comparison with the gold standard method.

Concordance with reference method	Number of positive samples	Gene	Ct Median	IQR	Ct Range	Number of samples with Ct >P95*
Concordant (Truly positive results)	148	N	31,91	29.92-33.27	29.41-38.48	6
		S	32,46	30.65-34.31	29.83-36.21	0
		Orf1ab	31,81	30.01-32.92	34.84-35.63	0
Concordant (Truly negative results)	59	None target detected	-		-	-
Discordant (false positive results)	5	N	37.46		36.92-38.80	4
		S	37.47		-	1
		Orf1ab	-		-	-
		≥2 targets detected	-		-	-
Discordant (false negative results)	53	None target detected	-		-	-
Total	265		-		-	-

^{*}P₉₅: The 95th percentile of each target;

197

198

199

200

201

202

203

204

205

206

207

Cobas® test obtained 4 false positive results with only detection of e gene and with Ct values from 37.57 to 38 while by TaqPathTM test 5 false positives were detected by detection of one target gene (n or s genes) only, and the Ct ranged from 36.92 to 38.8. False negative results were obtained by cobas® test for 87 samples, 30 of them with amplification of the two targets of the gold standard method; the rest of false negative samples (57/87) showed amplification of just one target gene. On the other hand, 53 false negatives were detected by TaqPathTM test; most of them (42/53) were positive by detection of only one target gene of the gold standard method, meanwhile the rest

(11/53), were positive by detection of both, n and orf1ab genes. There was agreement in 45 (85%) of the false negatives obtained by TaqPathTM test with cobas® test.

Discussion

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

To our knowledge, this is the first study which assesses the performance and accuracy of these techniques in serum samples for SARS-CoV-2. The goal of this study is to assess two commercial rRT-PCR assays for SARS-CoV-2 RNA detection in serum samples, to provide clinicians a useful tool in the management of the COVID-19. Although these commercial assays have not been validated for their use in serum or plasma samples, the extraction methods performed in this study are commonly carried out in serum or plasma samples for other viruses (10–12). The preferred method for diagnosis of SARS-CoV-2 is rRT-PCR of upper respiratory tract samples, via nasopharyngeal and oropharyngeal swabs or, in some cases, lower respiratory tract samples (13). However, SARS-CoV-2 have been detected in multiple samples, as saliva, stool, plasma and serum (8, 14). Detection of SARS-CoV-2 RNA in serum samples have been related to progression to a critical disease and death (4, 15) and with the cytokine storm (3). However, most of the studies perform in-house or commercial methods for SARS-CoV-2 detection are not validated in serum or plasma samples (4, 15). In our study the viraemia's percentage showed significant differences (p<0.001) in ICU patients respect patients admitted in the ward with the two rRT-PCR assays; supporting previous studies which indicate that presence of SARS-CoV-2 RNA in serum samples is more common in critical patients and could be considerated a prognostic indicator (15-17).

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

Comparison between the assessed rRT-PCR kits and the gold standard method showed high specificity and positive predictive values, over 90% in both techniques. These high values point out that a positive result of RNA detection of SARS-CoV-2 in serum samples of patients previously COVID-19 diagnosed are reliable, and should be taken into account for clinicians attending to the patient. Cobas® test showed four false positive results, all of them with the only amplification of e gene. According to manufacturer's indications, detection of the e gene without amplification of orf-lab region could be due to several factors, mutations in the amplification region of orf-1ab, low viral loads, presence of other sarbecovirus or other factors. These results should be considered as presumptive positive results and be retested (18). Moreover, 52 true positive samples had amplification of the e gene, so it was decided to consider the amplification of only this target as positive for several reasons. First, because the serum samples collected in this study belonged to previously diagnosed COVID-19 patients. Secondly, according to the WHO (19), SARS-CoV has only been reported just four times since the end of the epidemic on July 2003 (three times associated to laboratory accidents and another one in Southern China). So the probability of the samples with e gene amplification without any other targets are due to other sarbecovirus is very low, and other reports considered them as positive too (10). There were five false positive results with TaqPathTM test, all of them with just one target detected and with high Ct values (from 36.92 to 38.80). Even more, these Ct values were over the 95th percentile, which could suggest the probability to obtain these false positive results is low. Therefore, values over 37 are unlikely, and should not be considered, which is in agreement with the last manufacturer's indications (20). However, with this consideration, six concordant results considered as true positive

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

would turn into false negative results, decreasing sensitivity slightly to 72.68% but increasing specificity to 98.33% (supplementary table 1). On the other hand, the negative predictive values obtained with both cobas® test and TagPathTM test were low (40.82% and 52.68%, respectively), due to the high number of false negative results obtained (87 with cobas® Test and 53 with TaqPathTM test). Moreover, it is remarkable that there was a high coincidence of the false negative results between both assessed techniques, 85% TaqPathTM test being negative with cobas® Test. It is difficult to elucidate the reason of these false negative results, as the three employed rRT-PCR kits are commercial and the design is not available for the customers, presenting differences in the number of targets, and possibly in the sequence or the size of the amplicons, which cause differences in sensitivity of the techniques. Even more, the cobas® test is performed in the automatic close cobas® 6800 system, making more difficult to elucidate the nature of discrepancies. A possible reason is that these samples had low viral loads, decreasing the sensitivity of the assessed techniques. Also, the RNA eluted volume added to the PCR reaction could have influenced because it was the double with the gold standard method compared with the TaqPathTM test. Moving to onboarding to the clinical practice, both techniques can be easily implemented in the diagnosis of COVID-19 in the microbiology laboratory and they can be performed along with the rest of respiratory samples for the diagnosis of SARS-CoV-2. TaqPathTM test is more suitable performing a small number of tests at a time meanwhile the cobas® test should be more useful when it is necessary to analyze high amounts of samples

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

The present study has some limitations. First, the intrinsic analytical variability of PCR can have influenced in the results obtained. Another limitation is the type of sample used in this study. Although serum samples are accepted in the analysis of viraemias, the common samples used in most microbiology laboratories are plasma samples. In conclusion, this study shows that cobas® SARS-CoV-2 Test and TagPathTM COVID-19 CE-IVD RT-PCR Kit could be useful in SARS-CoV-2 viraemia detection in serum of diagnosed COVID-19 patients. For a better test performance, considering the detection of at least one target obtained with any technique, and in particular with a Ct value under 37 with the TaqPathTM assay. A viraemia positive result may help in handling COVID-19 patients, due to the relationship between viraemia and bad prognosis and mortality recently reported (4, 15). In addition, these techniques are easy to incorporate in the Microbiology laboratory routine for SARS-CoV-2 diagnosis. Finally it could open new treatment strategies based on early COVID-19 treatment (15). **Compliance with Ethical Standards: Funding:** The authors did not receive any fundings to do the study. **Conflict of Interest:** Authors do not have conflict of interest. **Ethical approval:** All participants enrolled voluntarily, and written informed consent was required to use data for analysis. The stydy was approved by the Hospital Universitario La Princesa independent ethics research committee (reference number 4267, acta CEIm 21/20).

References

- 304 1. Cheng ZJ, Shan J. 2020. 2019 Novel coronavirus: where we are and what we
- 305 know. Infection 48:155-163.
- WHO. 2020. Coronavirus disease (COVID-19) World Health Organization. 306 2.
- 307 3. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang
- 308 B, Ding J, Li F. 2020. Detectable serum SARS-CoV-2 viral load (RNAaemia) is
- 309 closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill
- 310 COVID-19 patients. Clin Infect Dis https://doi.org/10.1093/cid/ciaa449.
- 311 Xu D, Zhou F, Sun W, Chen L, Lan L, Li H, Xiao F, Li Y, Kolachalama VB, Li Y, 4.
- 312 Wang X, Xu H. 2020. Relationship Between serum SARS-CoV-2 nucleic
- 313 acid(RNAemia) and Organ Damage in COVID-19 Patients: A Cohort Study.
- 314 Clinical Infectious Diseases ciaa1085.
- 315 5. Eberhardt KA, Meyer-Schwickerath C, Heger E, Knops E, Lehmann C, Rybniker
- 316 J, Schommers P, Eichenauer DA, Kurth F, Ramharter M, Kaiser R, Holtick U,
- 317 Klein F, Jung N, Di Cristanziano V. 2020. RNAemia Corresponds to Disease
- 318 Severity and Antibody Response in Hospitalized COVID-19 Patients. Viruses
- 319 12:1045.
- 320 6. Chen W, Xu Z, Mu J, Yang L, Gan H, Mu F, Fan B, He B, Huang S, You B, Yang
- 321 Y, Tang X, Qiu L, Qiu Y, Wen J, Fang J, Wang J. 2004. Antibody response and
- 322 viraemia during the course of severe acute respiratory syndrome (SARS)-
- 323 associated coronavirus infection. Journal of Medical Microbiology 53:435–438.

- 324 Ji T, Liu Z, Wang G, Guo X, Akbar khan S, Lai C, Chen H, Huang S, Xia S, Chen 7.
- 325 B, Jia H, Chen Y, Zhou Q. 2020. Detection of COVID-19: A review of the current
- 326 literature and future perspectives. Biosensors and Bioelectronics 166:112455.
- 327 8. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, Wang Y-Y, Xiao G-F, Yan
- 328 B, Shi Z-L, Zhou P. 2020. Molecular and serological investigation of 2019-nCoV
- 329 infected patients: implication of multiple shedding routes. Emerging Microbes &
- 330 Infections 9:386–389.
- 331 9. Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescense
- 332 Probing) Instructions for use. Version 00.
- 333 10. Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H,
- 334 Akhayan S, Charpentier C, Chaix M-L, Descamps D, Calvez V, Marcelin A-G.
- 335 2017. Multicenter comparison of the new Cobas 6800 system with Cobas
- 336 Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV,
- 337 HBV and HCV viral load. Journal of Clinical Virology 96:49–53.
- 338 11. Barreiro P, Labarga P, Fernandez-Montero JV, Mendoza C de, Benítez-Gutiérrez
- 339 L, Peña JM, Soriano V. 2015. Rate and predictors of serum HCV-RNA >6 million
- 340 IU/mL in patients with chronic hepatitis C. Journal of Clinical Virology 71:63–66.
- 341 12. Loens K, Bergs K, Ursi D, Goossens H, Ieven M. 2007. Evaluation of NucliSens
- 342 easyMAG for Automated Nucleic Acid Extraction from Various Clinical
- 343 Specimens. Journal of Clinical Microbiology 45:421–425.
- 344 13. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, Scarlata S,
- 345 Agrò FE. 2020. COVID-19 diagnosis and management: a comprehensive review. J
- 346 Intern Med 288:192-206.

- 14. To KK-W, Tsang OT-Y, Yip CC-Y, Chan K-H, Wu T-C, Chan JM-C, Leung W-S,
- Chik TS-H, Choi CY-C, Kandamby DH, Lung DC, Tam AR, Poon RW-S, Fung
- 349 AY-F, Hung IF-N, Cheng VC-C, Chan JF-W, Yuen K-Y. 2020. Consistent
- Detection of 2019 Novel Coronavirus in Saliva. Clinical Infectious Diseases
- 351 71:841–843.
- 352 15. Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J,
- Ursing J. 2020. SARS-CoV-2 RNA in serum as predictor of severe outcome in
- 354 COVID-19: a retrospective cohort study. Clinical Infectious Diseases ciaa1285.
- 355 16. Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S,
- 356 Yamamoto F, Murugesan K, Kurzer J, Zehnder J, Pinsky BA. 2020. High
- Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease.
- 358 Clinical Infectious Diseases ciaa1054.
- 359 17. Veyer D, Kernéis S, Poulet G, Wack M, Robillard N, Taly V, L'Honneur A-S,
- Rozenberg F, Laurent-Puig P, Bélec L, Hadjadj J, Terrier B, Péré H. 2020. Highly
- sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential
- 362 clinical value. Clinical Infectious Diseases ciaa1196.
- 363 18. cobas® SARS-CoV-2 Qualitative assay for use on the cobas® 6800/8800
- 364 Systems.

- 365 19. WHO. SARS (Severe Acute Respiratory Syndrome). World Health Organization.
- 366 20. ThermoFisher Scientific. 2020. TaqPathTM COVID-19 CE-IVD RT-PCR Kit
- 367 INSTRUCTIONS FOR USE.

Supplementary table 1. Comparison values calculated considering the Ct> P₉₅ as a

negative result. 370

369

	TaqPath™ COVID-19 Kit	cobas® SARS-Cov-2 Test
Sensitivity	72.68%	55.84%
Specificity	98.33%	93.75%
Positive predictive value	99.3%	96.49%
Negative predictive value	52.68%	40.82%
Kappa coefficient	0.55	0.35